RecruitingLipoprotein Disorder
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
Eligible age
18–80 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Sponsor: Kylonova (Xiamen) Biopharma co., LTD.
You may qualify if…
- ✓ Age 18 to 80 years
- ✓ Clinical diagnosis of atherosclerotic cardiovascular disease with elevated Lp(a)
- ✓ Other inclusion criteria applied per protocol.
You may not qualify if…
- ✕ Have moderate to severe heart failure (New York Heart Association \[NYHA\] Functional Classification III or IV during Screening) or last known left ventricular ejection fraction \<30%
- ✕ Have uncontrolled hypertension (systolic blood pressure \[SBP\] ≥160 mmHg or diastolic blood pressure \[DBP\] ≥100 mmHg)
- ✕ Have uncontrolled cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 3 months prior to randomization
- ✕ Have had any malignancy within 5 years prior to randomization (except for non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma that has been successfully treated)
- ✕ Other exclusion criteria applied per protocol.
Where it's recruiting
California
Los Angeles · San Diego · Santa Maria
Florida
Boca Raton · Clearwater · Daytona Beach · Doral …
Georgia
Atlanta · Columbus
Louisiana
Lake Charles
Nevada
Las Vegas
North Carolina
Morehead City
Source: ClinicalTrials.gov · NCT07327840 · last updated 2026-06-25